Navigation Links
Herborium Group Shareholders Update
Date:10/27/2011

SADDLE BROOK, N.J., Oct. 27, 2011 /PRNewswire/ -- Herborium Group, Inc., (Pinksheets: HBRM) www.herborium.com, a Botanical Therapeutics™ company, announced the following update today.

Dr. Agnes Olszewski, Chairmen and a CEO of Herborium stated: "These are truly exciting times for our Company. Firstly, we have continued our planned advancement to the Bulletin Board exchange by maintaining Herborium' Current Information Status– the highest tier attainable on OTC Pink Sheet Markets.  Additionally, we have many developments coming to fruition as a result of series of new initiatives we have undertaken in the Natural Medicine products space. These developments will play a significant role in Herborium's growth and future."

Dr. Olszewski continued, "As these developments are released to the public it will be important for all current and future shareholders to know what represents a value added and uniqueness of our Company, and where we are progressing along our business plan. Therefore, we felt it necessary to release a short overview of our business opportunity map, before we actually begin discussing the goals we have accomplished and those we are pursuing."

First and foremost Herborium is a natural medicinal products company with a number of established, proprietary, patent and/or trade secret protected natural medicinal products – Botanical Therapeutics®. Our Botanical Therapeutics are uniquely qualified and positioned to address numerous highly important health concerns in both the medical and social spaces. These products are differentiated from most of other natural medicinal products on a market by three distinct characteristics 1) scientific and clinical testing 2) each product targets high demand area of medical needs 3) intellectual property protection. In addition, number of our Botanical Therapeutics is beyond the development stage and is being commercialized or is ready for commercialization. Herborium has also secured a pipeline of product extensions that will assure the Company's positioning  in the marketplace and stream of revenues. The combined market for non-traditional treatments and healthy lifestyles expenditures in the USA alone exceeds $50 Billion with natural medicine being responsible for over 70% of the spending.  The overall potential for botanical drugs may exceed $3 trillion USD worldwide.

Herborium lead Botanical Therapeutic® - AcnEase® , (www.acnease.com is all botanical ingredients based medicine that addresses the need for an effective and safe solution  in the treatment of acne and symptoms of Rosacea.. The National Institute of Arthritis and Musculoskeletal and Skin Diseases Website (Division of National Institutes of Health) reports that in the US alone nearly 85% of people between the ages of 12 and 24 develop acne, and 60 million Americans have existing acne. Rosacea afflicts over 17 million Americans and is a much more prevailing problem in Europe with no known solution in sight.  AcnEase is an all natural systemic product that safely and effectively targets acne and Rosacea in both females and males of all ages.  The results of AcnEase have been impressive with up to 95% of patients seeing improvement after the first course of treatment. Those suffering from symptoms of Rosacea noted up to 90% improvement in skin related symptoms as well as GI and opthomological symptoms.

During the recent months, a significant progress has been made through our marketing efforts, with special focus on Social Marketing strategy, to capitalize on the unique benefits of AcnEase, and on growing consumer needs, exasperated by a recent withdrawal of the Roche Pharmaceutical product - Accutane , the only systemic competition for AcnEas, and by the increasing demand for natural medicines.

Those and other business progress milestones are going to be a subject in our forthcoming communications.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.  

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: DrAgnes@Herborium.com


'/>"/>
SOURCE Herborium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
(Date:6/23/2016)... 23, 2016 The Biotechnology industry ... to present great opportunities to investors. Stock-Callers.com assesses the ... Corp. (NYSE: XON ), Vertex Pharmaceuticals Inc. ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... and receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):